Jump to content

Adecatumumab

From Wikipedia, the free encyclopedia
(Redirected from C6552H10080N1740O2052S46)
Adecatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6552H10080N1740O2052S46
Molar mass147533.60 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.[1]

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate[2] and breast cancers.[3] Phase II results were published in 2010.[4]

References

[edit]
  1. ^ "Adecatumumab - Amgen/Merck Serono". Adis Insight. Springer Nature Switzerland AG.
  2. ^ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.
  3. ^ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". British Journal of Cancer. 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555.
  4. ^ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. (February 2010). "An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer". Annals of Oncology. 21 (2): 275–82. doi:10.1093/annonc/mdp314. PMID 19633042.